Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>RemeGen granted exclusive rights to develop and commercialize Telitacicept worldwide (excluding Greater China) to Vor Biopharma for $125M. Innovent Biologics received a first-in-class weight loss drug approval in China.</li>
<li>Daiichi Sankyo received FDA approval for Datroway for the treatment of certain types of non-small cell lung cancer (NSCLC). SanBio now expects Akuugo approval in H2FY26, instead of Q2FY26.</li>
<li>Otsuka in-licensed HBM7020 from Harbour BioMed for an upfront payment of $47M and near-term milestones. Glenmark Pharmaceuticals has launched Beigene’s Tevimbra in India for NSCLC.</li>
</ul>


RemeGen granted exclusive rights to develop and commercialize Telitacicept worldwide (excluding Greater China) to Vor Biopharma for $125M. Innovent Biologics received a first-in-class weight loss drug approval in China.
Daiichi Sankyo received FDA approval for Datroway for the treatment of certain types of non-small cell lung cancer (NSCLC). SanBio now expects Akuugo approval in H2FY26, instead of Q2FY26.
Otsuka in-licensed HBM7020 from Harbour BioMed for an upfront payment of $47M and near-term milestones. Glenmark Pharmaceuticals has launched Beigene’s Tevimbra in India for NSCLC.


APAC Healthcare Weekly (June 29)- RemeGen, Innovent, Daiichi, SanBio, Otsuka, Chugai, Glenmark

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Last week, PCVX had pneumococcal vaccine data that could seriously challenge PFE’s market leading Prevnar 20.</li><li>TVTX celebrated full FDA approval of its IgAN drug, just in time for new KDIGO guidelines. </li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Last week, PCVX had pneumococcal vaccine data that could seriously challenge PFE’s market leading Prevnar 20.TVTX celebrated full FDA approval of its IgAN drug, just in time for new KDIGO guidelines. 

Biopharma Week in Review - September 9, 2024

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/remegen-co-ltd" target="_blank" data-smartkarma-citation="entities:29191:1" rel="noopener">Remegen (9995 HK)</a> entered an exclusive outlicensing agreement with <a href="https://www.smartkarma.com/entities/abbvie-inc" target="_blank" data-smartkarma-citation="entities:1135:1" rel="noopener">Abbvie Inc (ABBV US)</a>  regarding RC148, a novel investigational PD-1/ VEGF bispecific antibody drug candidate for an upfront payment of $650M.</li>
<li>Remegen is eligible to receive up to $4.95B in development, regulatory, and commercial milestone payments, as well as tiered double-digit royalty payments on net sales outside the Greater China region.</li>
<li>RC148 is currently being developed in China by Remegen as a monotherapy and in combination for treating patients with various advanced malignant solid tumors, including certain lung cancers.</li>
</ul>



Remegen (9995 HK) entered an exclusive outlicensing agreement with Abbvie Inc (ABBV US)  regarding RC148, a novel investigational PD-1/ VEGF bispecific antibody drug candidate for an upfront payment of $650M.
Remegen is eligible to receive up to $4.95B in development, regulatory, and commercial milestone payments, as well as tiered double-digit royalty payments on net sales outside the Greater China region.
RC148 is currently being developed in China by Remegen as a monotherapy and in combination for treating patients with various advanced malignant solid tumors, including certain lung cancers.


Remegen (9995 HK): New Licensing Deal With AbbVie Brings $650M Upfront Cash

United States

Vor BioPharma Inc. operates as a clinical stage cell therapy company. The Company specializes in developing novel therapies for treating cancer. Vor BioPharma focuses on discovering technologies that can enable selective targeting of cancer cells without impacting normal cells. Vor BioPharma serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Vor BioPharma (VOR US)

APAC Healthcare Weekly (June 29)- RemeGen, Innovent, Daiichi, SanBio, Otsuka, Chugai, Glenmark

Last week couple of Chinese companies signed outlicensing deals with international players. Innovent got weight loss drug approval in China....

Tina Banerjee

Biopharma Week in Review - September 9, 2024

Last week, PCVX had pneumococcal vaccine data that could seriously challenge PFE’s market leading Prevnar 20. TVTX celebrated full FDA approval of...

Water Tower Research

Remegen (9995 HK): New Licensing Deal With AbbVie Brings $650M Upfront Cash

Remegen inked an exclusive outlicensing deal with AbbVie for RC148, an investigational PD-1/ VEGF bispecific antibody drug candidate for an upfront...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)